Can Peptide Companies Advertise on Google Ads?

Key takeaways

There is no single “peptide policy.” Peptide advertisers get judged by several overlapping policies at once — Healthcare and Medicines, Unapproved Substances, Misrepresentation, and Merchant Center product data policy.
What you sell matters less than how your site presents it. Identical products pass or fail depending on claims, labelling, checkout gating, and documentation.
Research-use suppliers, telehealth clinics, and compounding pharmacies each take a different approval path. Copying another company’s setup is one of the most common reasons for suspension.
Approval is a website and data problem first, a campaign problem second.

The short answer

Yes — some peptide companies advertise on Google successfully. No — not every peptide company can, and nobody can promise you a specific outcome, because Google makes the final call on every account, domain and product.

That answer sounds unsatisfying until you understand what actually drives it. Google isn’t evaluating “peptides” as a category with a yes/no switch. It is evaluating a set of signals across your website, your product data, your claims and your business entity, then applying several policies simultaneously. Two companies selling the same molecule at the same price can land in completely different places because one of them reads as a documented supplier and the other reads as an unapproved-substance seller making health claims.

What we mean by “peptide company”

This article covers research-use peptide suppliers, telehealth and wellness clinics prescribing peptide therapies, compounding pharmacies, wholesale suppliers, and manufacturers. Those are five different advertising problems that get lumped into one word.

Which policies actually apply

Most agencies quote one policy and stop. In practice, peptide accounts are reviewed against several at once:

Healthcare and medicines. Governs prescription drug promotion, pharmacy certification, and which advertiser types may promote which treatments in which countries. Relevant if there is any prescribing, telehealth or pharmacy relationship.
Unapproved substances. The policy most peptide advertisers actually collide with. Speculative, experimental or non-approved substances are restricted, and language that implies human consumption pushes a product into this bucket fast.
Misrepresentation. The quiet account-killer. Missing business identity, thin contact information, unclear refund and shipping terms, unverifiable certifications, or implied outcomes without support.
Merchant Center product data policy. Applies to Shopping and Performance Max. Product titles, attributes, images and landing pages are all reviewed as data, not just as marketing.
Local legal requirements. Country-level rules layered on top of Google’s own. A setup that clears in one market can be refused in another.

Because the policies overlap, a single fix rarely resolves a suspension. A site can be perfectly clean on medical claims and still be disapproved for identity and transparency gaps.

Why presentation decides the outcome

The most useful mental model: Google’s reviewers and automated systems are trying to determine what your product is for. Everything on your site is evidence toward that determination.

Signals that push a listing toward “consumer therapeutic” treatment:

Dosage protocols, cycles, stacking guidance, or “how to use” content
Before/after imagery, weight-loss or performance outcomes, condition names
Reviews describing personal use
Bundling with syringes, bacteriostatic water, or injection supplies on the same page

Signals that support a documented research-supply reading:

Consistent research-use-only labelling on product pages, cart and checkout — not just in a footer disclaimer
Certificates of analysis, purity data, batch numbers, third-party testing published and accessible
Clear entity information: legal name, registered address, contact routes, policies
Product data that describes the compound and specification instead of an outcome

A common trap

Teams often clean the pages they intend to advertise and leave the rest of the site untouched. Reviews consider the domain, not the landing page. A single blog post about dosing can undo a compliant product catalogue.

The four approval paths by business type

Business type	Primary risk	Typical viable route
Research peptide supplier	Unapproved substances, misrepresentation	Search on non-consumption intent, strict research-use presentation, documentation-heavy site, Shopping only after Merchant Center is stable
Telehealth / wellness clinic	Healthcare policy, certification requirements	Certification and entity verification first, service-level messaging, lead-gen structure with offline conversion tracking
Compounding pharmacy	Pharmacy certification, prescription claims	Pharmacy certification where applicable, brand and non-product terms, careful geographic scoping
Wholesale / manufacturer	Misrepresentation, B2B intent mismatch	B2B positioning, gated ordering, capability and specification content, Search plus retargeting rather than Shopping

Choosing the wrong path is expensive. A supplier that copies a telehealth clinic’s messaging inherits healthcare-policy exposure it cannot satisfy; a clinic that copies research-use language undermines the very certification it needs.

What to do before you launch anything

Full-site policy pass. Every product page, blog post, FAQ, review and image — not the landing page alone.
Entity and transparency review. Business identity, contact, shipping, returns and terms, all reachable in two clicks.
Documentation publishing. COAs, testing and specifications online and linkable.
Tracking before spend. Server-side or enhanced conversions, consent handling, and de-duplicated conversion actions so early data is usable.
Merchant Center diagnostics (if Shopping matters) before any feed submission at scale.
Then campaign structure and launch, starting narrow enough to survive a review cycle.

Founder Question

“Our competitor is running ads right now. Why can’t we just do what they’re doing?”

Our Perspective

Because you can only see their ads — not their entity verification status, their certifications, their Merchant Center history, or how many suspensions it took to get there. Copying visible output while missing the invisible configuration is how accounts inherit risk without inheriting the protections. We would rather map your own path than reverse-engineer someone else’s.

Practical Recommendation

Decide which of the five business types you actually are before writing a single ad — research supplier, telehealth clinic, compounding pharmacy, wholesaler or manufacturer. The approval path differs for each, and copying another company’s setup is the most common self-inflicted suspension.
Audit the whole domain, not the pages you plan to advertise. Reviews consider the site as a body of evidence about what your product is for, so legacy dosing content undoes a clean catalogue.
Sequence Search before Shopping. Search has a narrower review surface than Merchant Center product data, so it is usually the cheaper place to establish a stable account history.

What we learned

Every peptide company is different, but in our experience, businesses that clearly separate research-use messaging from consumer health messaging, publish transparent quality documentation, and maintain clean product data tend to have a stronger foundation for Google Ads than those that don't. The accounts that struggle most are usually the ones that fixed a landing page and left the rest of the domain telling a different story.

Frequently asked

Is it against Google's rules to sell peptides?

Selling peptides is not itself prohibited. Promoting them for human consumption, for treatment of conditions, or without the transparency Google expects is what triggers restriction and suspension.

Can I run Search ads but not Shopping?

Often yes, and it is frequently the right sequence. Search has a narrower review surface than Merchant Center product data, so many accounts stabilise on Search first and add Shopping later.

Will using a different domain solve a suspension?

No. Domain switching without fixing the underlying signals is treated as circumvention, which escalates the problem rather than resolving it.

Next step

If you want this applied to your account and your site rather than read in the abstract, book a 30-minute strategy session. We will look at the domain before the call.

Book a Strategy Call

Can Peptide Companies Advertise on Google? (2026 Reality Check)